Anti-Cancer Compounds for Treatment of Cancer and Autoimmune Inflammation (RFT-531)

Invention Summary

graphgraph

Cyclo-oxygenase-2 (COX-2) over-expression is a known marker for cancer cell initiation, growth and consequent metastasis. COX-2 catalyzes the oxidation of omega 6 fatty acid - arachidonic acid, producing metabolites such as prostaglandins that are known to initiate various cancers. Scientists at North Dakota State University have developed an anti-cancer compound that indirectly targets the over-expression of COX-2, with potential to treat multiple cancer types. Specifically, this compound targets delta-5-saturase (D5D) and provides anti-cancer benefits in two ways: 1. Down regulation of 'pro-cancer' prostaglandins and 2. elevated production of anti-cancer compound, dihomo-γ-linolenic acid (DGLA) and its metabolite, 8- hydroxy octanoic acid (8-HOA). A common strategy has been to completely block COX-2, shutting down its beneficial aspects in order to eliminate the negative aspects. NDSU's technology selectively turns down COX-2's negative aspects, while taking advantage of COX-2 over expression to boost production of 8- HOA. To our knowledge, this technology represents the first anti-cancer compound to take advantage of COX-2 over-expression in tumors and has been successfully tested in the lab using mice bearing solid tumors for breast, colon, pancreatic, and lung cancers.

Benefits

  • Targeted strategy with tested application in cancer management and prevention
  • Probable treatment in both benign and metastatic (solid or invasive) tumors
  • Effective in multiple tumor types - reduced growth rate of tumors by 50% to 70% in mice bearing breast, colon, pancreatic, and lung tumors
  • Preliminary data on combination therapy with conventional chemotherapeutics reflects additional restriction of tumor growth and metastasis
  • Additionally, this targeted strategy can be used for treatment of autoimmune and inflammatory conditions

Phase of Development

This technology has successfully completed laboratory testing with reproducible results.

Patents

This technology is the subject of Issued U.S. patent no. 10,639,313.

Status

This technology is available for licensing/partnering opportunities.

Contact

Saurabhi Satam, Business Development and Licensing Associate
ssatam(at)ndsurf(dot)orgtumors

(701)231-8173

Downloads

Download the technology summary (PDF, 280.97 KB)

NDSURF Tech Key

RFT, 531, RFT531

Inquire about this technology >